GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Long-Term Capital Lease Obligation

BeiGene (FRA:49BA) Long-Term Capital Lease Obligation : €20 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is BeiGene Long-Term Capital Lease Obligation?

BeiGene's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €20 Mil.

BeiGene's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 (€24 Mil) to Sep. 2023 (€24 Mil) but then declined from Sep. 2023 (€24 Mil) to Dec. 2023 (€20 Mil).

BeiGene's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€38 Mil) to Dec. 2022 (€33 Mil) and declined from Dec. 2022 (€33 Mil) to Dec. 2023 (€20 Mil).


BeiGene Long-Term Capital Lease Obligation Historical Data

The historical data trend for BeiGene's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Long-Term Capital Lease Obligation Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.25 24.18 38.09 32.58 20.40

BeiGene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.58 30.40 23.83 23.87 20.40

BeiGene  (FRA:49BA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

BeiGene Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of BeiGene's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (FRA:49BA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Long-Term Capital Lease Obligation
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines